FDAapproval84% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Hikma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Supporting Context
- Therapeutic area
- Neurology · Mood Disorders
- Sub-indication
- General
Related signal: Hikma's Lithium Carbonate ANDA Receives Approval Status from FDA